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procured, provides alternatives to adjust the budget available and release financial 
resources for cost effective and sustainable interventions .
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Objectives: To be effective, osteoporosis (OP) therapy must be taken consistently 
and as prescribed. Persistence is critical for successful outcomes, including fracture 
risk reduction. Few studies compare the persistence of oral bisphosphonate (BPs), IV 
BPs and denosumab beyond 1 year. This retrospective database analysis evaluated 
2-year persistence to oral BPs, IV BPs and denosumab following treatment initiation 
and the risk of treatment discontinuation. MethOds: From the German IMS®LRx 
database, we included women aged ≥ 45 years who initiated an OP treatment after 
1-July-2010 (index date = treatment initiation) with ≥ 2 years of follow-up until 
31-Dec-2014. Persistence (prescription refill gap ≤ 60 days and no drug switch) was 
measured for 2 years from index date, and a Cox proportional hazard regression 
model was used to estimate the risk of treatment discontinuation (i.e. non-persis-
tence). Results: Data from 159,993 women were included in the analysis. Two years 
after treatment initiation, 39.8 % of those receiving denosumab (n= 21,154), 24.8 % 
receiving IV ibandronate (n= 20,472), 21.2 % receiving IV zoledronic acid (n= 3,966), 
and 16.7 %„Ÿ17.5 % of those receiving oral BPs were persistent. Compared with those 
receiving denosumab, women receiving IV ibandronate or IV zoledronic acid were 
at higher risk of treatment discontinuation (HR [95% CI]: 1.65 [1.61-1.69] and 1.28 
[1.23-1.33] respectively; p< 0.001 for both). Moreover, women treated with oral BPs vs 
denosumab showed a two-fold risk of treatment discontinuation (HR [95% CI]: 2.02 
[1.98-2.06] for alendronate, 2.02 [1.95-2.09] for ibandronate and 1.96 [1.91-2.01] for 
risedronate; p< 0.001 for all). cOnclusiOns: In our database study of women ini-
tiating BPs (oral or IV) or denosumab in routine clinical practice, 2-year persistence 
was highest for denosumab (1.5-2 times higher). Moreover, compared to denosumab, 
women treated with oral or IV BPs were at higher risk of treatment discontinuation. 
Such improved persistence may improve clinical outcomes, including increased 
fracture risk reduction.
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Objectives: We aim to examine the association between self-reported RD and early 
retirement by using large real-world observational data in Portugal. MethOds: We 
used individual level data from the national, population-based EpiReumaPt study 
(September 2011 to December 2013). 10,661 inhabitants were randomly surveyed in 
order to capture and characterize all cases of RD within a representative sample of 
the Portuguese population, which were stratified by administrative territorial units 
(NUTSII). In this analysis we used all participants aged between 50 and 65 years old, 
near the official retirement age (N= 2,792; females: 1,727). The association of self-
reported RD and early retirement was tested using logistic regression. All estimates 
were computed as weighted proportions, in order to take into account the sampling 
design. Results: 29.9% of the Portuguese population with ages between 50 and 64 
years old were officially retired. Among these, 43.2% were retired due to ill-health, 
which in turn about a third (30.4%) was specifically due to RD. Thus, 13.1% of all 
retirees self-reported RD as the main reason for early retirement. More than a third 
(34.2%; females: 46.3%) of all study population self-reported RD, being also more 
likely to self-report other main chronic disease (OR: 3.4; CI: 2.53-4.65; p< 0.001). 35.2% 
of RD respondents were retired versus 27.2% of those non-RD (p= 0.025). Prevalence 
of self-reported RD seems to be associated with early retirement (unadjusted OR: 
1.45; CI: 1.05-2.01; p= 0.025). Some other characteristics are also associated with 
early retirement, in particular older age, male gender and presence of other chronic 
diseases. RD association tends to be independently associated with early retire-
ment (adjusted OR: 1.41; CI: 1.03-1.95; p= 0.031). cOnclusiOns: These results are 
similar with previous data from the National Health Survey conducted in Portugal 
nearly a decade ago and confirms the impact that self-reported RD still have on 
early retirement.
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Objectives: To assess demographic and disease characteristics of rheumatoid 
arthritis (RA) patients starting treatment with biologic disease-modifying anti-rheu-
matic drugs (DMARDs) in observational studies. MethOds: Systematic review of 
published observational studies in adult patients with RA treated with one of three 
biologic DMARDs (etanercept, rituximab, tocilizumab). We identified eligible studies 
through electronic searches of the MEDLINE and EMBASE databases. Two reviewers 
screened the articles independently. We extracted study characteristics such as 
location and calendar period, demographics of study populations, dose, frequency 
and concomitant therapies, and baseline characteristics such as disease duration, 
the most common bone disease and its incidence is rapidly increasing with the 
aging population. Even if curable, it is often left untreated causing a moderate use 
of economic resources that could be avoided.
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Objectives: Hospital Parc Taulí and Johnson & Johnson, partnered in a program 
to design and implant a fast track program for knee joint replacement. The objec-
tive was to decrease morbidity, functional convalesce, length of stay and increase 
patient and professionals satisfaction efficiently. MethOds: The implementation 
included 3 phases and two multidisciplinary Workgroups. Clinical aspects based on 
evidence, combined with organizational optimization, resources distribution and 
process redesign. Phase I: evaluation, nourished by Kaizen methodologies, Lean 
and 6 Sigma processes, Blum and Taylor laborer environment and Alex Faicknet 
Osborn group dynamics were taken under consideration. Phase II: Implantation, 
using Taylor dynamics to define the strategies to produce improvement on target 
indicators. Phase III: Monitoring, both from length of stay, security aspects such as 
morbidity, mortality, readmission rates, patient and professional satisfaction, and 
economic impact. Results: The length of stay is influenced by factors such as 
patient profile and organizational aspects. Empowered patients are more active. 
A new patient pathway was developed, initiated when admitted to discharge and 
post-operative follow up. Improvement on healthcare results, increasing patient and 
professional’s satisfaction, and reducing 50% length of stay, resulting on significant 
economical savings. cOnclusiOns: Analyzing the patient pathway through an 
analysis methodology, reingeniery and diagnosis healthcare process (in outcomes 
and in direct cost), the patient involvement in the whole process can result not only 
in important efficiency improvement, but also improve the working environment 
and enhanced team work culture for a continuous process improvement.
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Objectives: The emergence of biosimilars for blockbuster therapies such as 
Remicade, Humira, Enbrel and Rituxan/MabThera is changing the paradigm by which 
traditional market access decisions are made for biologics. Furthermore, the regula-
tory pathway in Europe and the U.S. has raised uncertainties among clinicians regard-
ing both the efficacy and safety of biosimilar molecules. The objectives of our research 
were to (1) understand the evolving mechanisms for biosimilar market access, (2) 
identify the key stakeholders involved in access decisions or influence and (3) deter-
mine the value drivers of biosimilars across diverse stakeholder groups. MethOds: 
A large sample of stakeholders (n= 271) were engaged, including clinical specialists, 
payers and patients, across Europe and in the U.S. We performed in-depth qualita-
tive interviews to gain an understanding of the current landscape for biologics and 
expectations for biosimilars, focusing on RA, Ulcerative Colitis, Crohn’s Disease and 
Psoriasis. Results: Our research indicates the fundamental understanding of bio-
similars is inconsistent both within stakeholder groups and across different groups. 
Furthermore, for clinicians, a lack of accurate understanding of biosimilars can be a 
substantial driver of negative perception and a key barrier to anticipated adoption. 
Overall, each stakeholder group that will influence biosimilar market access has dif-
ferent value needs and expectations from biosimilars. cOnclusiOns: Our findings 
highlight the need for a more consistent definition of biosimilar and clinical data 
requirements and a tailored approach to value communication for key influencers 
and stakeholders in the biosimilar value chain.
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Objectives: In 2014, the budget for high cost drugs in Dominican Republic (DR) was 
USD 107 million, accounting for 51% of the MoH budget for medicines. Resources 
allocated for the 2015 budget were USD 49 million, leaving a shortfall of USD 62 
million. The MoH requested technical assistance from the USAID funded SIAPS 
project to conduct an evidence based analysis of the 98 products included in the 
list. MethOds: Stage 1. Gathering of Evidence and Analysis; SIAPS consultant ana-
lyzed the therapeutic benefits and cost, and proposed 4 priority levels: Priority 1: 
Medicines included in the WHO Essential Medicine List; Priority 2: Included in the 
list of a Central America and DR procurement mechanism (COMISCA); Priority 3: Not 
included in the preceding groups but with scientific evidence of therapeutic benefits 
and approved by EMA and FDA; Priority 0: Medicines for which evidence on benefits 
was insufficient or for which better/cheaper alternatives were available. Stage 2. 
Review and approval by national scientific committee. During a two-day workshop, 
clinical specialists reviewed the proposed priority groups, consulted literature and 
proposed modifications supported by scientific evidence. Results: In the plenary 
session, the scientific committee, agreed by consensus on the final version of the 
high cost drugs list to be procured in 2015. Of the 98 medicines, 22 were on the 
WHO list and 17 were on the COMISCA; 14 of the remaining 59 medicines were also 
included because there was scientific evidence of its benefits. Total of 45 medicines 
were removed by consensus, with a budget decrease of 53 % and savings of USD 
21 million. cOnclusiOns: A review -based on evidence- followed by a consensus 
reached with clinical specialists allowed to select the number of products to be 
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Objectives: To understand current Risk Sharing Agreements (RSAs) for immu-
nomodulators for rheumatoid arthritis, psoriasis, and psoriatic arthritis in 11 mar-
kets aimed to optimize specific RSA strategies/ payer partnerships. MethOds: 
Review of publicly available health authority websites and peer-reviewed journals. 
Interviews with payers and stakeholders who influence RSA decisions and ex-
pharma executives for validation and gap filling. Results: USA manufacturers 
negotiate RSAs with private health insurers and states. Payers in USA integrate 
financial risks with manufacturers using outcome based agreements (OBAs). Canada 
established RSAs with Provinces and use financial based agreements (FBAs) but 
some are OBAs. France requires volume based FBAs for new high-priced therapies 
to limit budget impact. Germany uses FBAs at the sickness fund level rather than 
the Gemeinsamer Bundesausschuss (G-BA) level because sickness funds manage 
their own budgets. Some OBAs exist with clearly defined outcomes. Italy negotiates 
RSAs at the national level for new therapies entering the market ranging from FBAs 
to OBAs depending on the specific therapy and target patient population. Italy may 
also require manufacturers to incorporate drug monitoring registries in the RSA. In 
Spain performance based OBAs are used for new therapies with nominal additional 
benefit at the regional level with clearly established outcomes. Netherlands and 
Sweden use evidence development (CED) agreements for high priced products to 
generate cost effectiveness data. In Switzerland, RSAs are new and mostly FBAs 
and mainly for orphan disease therapies and off-label indications with price cap-
ping. In the UK,FBAs with few OBAs are used affecting product price but are not 
rebate based. Australian RSAs are mostly FBAs and are referred to as “Deeds of 
Agreement.” cOnclusiOns: With high-cost immunomodulators, authorities are 
shifting towards integrating RSAs in price negotiations to optimize budget expec-
tations prior to launch. Europe prefers FBAs to OBAs which often require clearly 
defined outcomes.
SySTeMic diSorderS/condiTionS – clinical outcomes Studies
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Objectives: This study compared adverse outcomes and resource use in patients 
treated with tapentadol prolonged-release (PR) with those treated with morphine 
controlled-release (CR) and oxycodone CR. MethOds: Data were from the Clinical 
Practice Research Datalink, a database derived from UK primary-care. Patients pre-
scribed tapentadol PR between May 2011 and December 2014 were matched to two 
groups of controls treated with either morphine CR or oxycodone CR on gender, age, 
pain duration, pain site and aetiology, Charlson index and prior analgesia. Rates 
of adverse events (constipation and nausea/vomiting) were compared by adjusted 
hazard ratio (aHR). Rates of primary-care contacts, accident and emergency con-
tacts, outpatient clinic letters and, for a subset of patients linked to Hospital Episode 
Statistics (HES), inpatient admissions were compared using incident rate ratios (IRRs) 
derived from Poisson regression. Results: 1,176 patients prescribed tapentadol PR 
were identified; 1,103 (93.8%) had a pain diagnosis. Of these 789 (67.1%) were matched 
to morphine controls and 557 (47.4%) to oxycodone controls. Compared with con-
trols, adverse events with tapentadol PR treatment were reduced: aHR= 0.643 (95% 
CI 0.459–0.901; p= 0.010) versus morphine CR and 0.505 (0.335–0.763; p= 0.001) ver-
sus oxycodone CR. Compared with morphine CR, primary-care contacts (IRR= 0.817; 
0.786–0.850), accident and emergency attendance (0.699; 0.560–0.870) and outpatient 
letters (0.715; 0.543–0.939) were also reduced. For oxycodone CR, the respective figures 
were 0.776 (0.706–0.840), 0.840 (0.639–1.103) and 0.545 (0.400–0.739). For the subset of 
HES-linked patients the rates of inpatient admissions were 0.723 (0.590–0.884) and 
0.458 (0.357–0.585) vs. morphine CR and oxycodone CR, respectively. cOnclusiOns: 
Tapentadol PR was associated with significantly fewer adverse gastrointestinal events 
than morphine CR or oxycodone CR. There was also significantly reduced primary- 
and secondary-care resource use. As with all observational studies, potential bias 
due to residual confounding and confounding by indication should be considered.
PSy2
clinical and econoMic Burden of PulMonary excerBaTionS in 
PaTienTS WiTh cySTic fiBroSiS Who are hoMozyGouS for The f508del 
MuTaTion
O’Sullivan AK1, Signorovitch JE2, Fang A2, Wagener J3, Hodgkins P1
1Vertex Pharmaceuticals, Boston, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3University 
of Colorado, Aurora, CO, USA
Objectives: To assess the clinical and economic burden of pulmonary exacerba-
tions (PEx) in patients with cystic fibrosis (CF) and homozygous for the F508del 
CFTR gene mutation. MethOds: Medical chart data from patients with CF ≥ 12 
years old were collected in France, Germany, Italy, Spain, Australia and Canada. 
Demographics, clinical characteristics, and selected resource utilization were 
obtained for a 12-month baseline period and a follow-up period ranging from 2-36 
months. The frequency of PEx and associated resource utilization was assessed 
overall and by age (12-17, ≥ 18 years) and lung function (percent predicted forced 
expiratory volume in 1-second [ppFEV1] ≥ 70%, 41-69%, ≤ 40%). Descriptive analyses 
were conducted. Results: Data for 523 patients were included. Baseline mean 
± SD age was 24.8 ± 9.5 years and mean ± SD ppFEV1 was 67.1 ± 22.9%. During 
disease activity and lab measurements. Results: 106 papers met our inclusion 
criteria. Studies were published between 2003 and 2015 and mostly from Europe; 
39 included patients starting etanercept, 36 included patients starting rituximab 
and 32 patients starting tocilizumab. Mean age ranged between 42.9 and 63.3 years, 
78.2% were female. The drugs were given in combination with methotrexate and/or 
other traditional DMARDs in over two thirds of the studies. Mean disease duration 
varied between 4 and 17.5 years, baseline disease activity 28 scores between 4.3 and 
7.0, and baseline health assessment questionnaire values between 1 and 2.9. The 
mean percentage of rheumatoid-factor positive patients was 76.4%. Reporting of 
comorbidities and smoking status was generally poor, with only few studies provid-
ing detailed data. cOnclusiOns: This systematic review of data from observational 
studies and clinical databases indicates that the characteristics of RA patients start-
ing biological DMARDs outside clinical trials in the real world varied widely. These 
observational data will now be compared with clinical trial data but it seems likely 
that some patient groups were not well represented in the trials.
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Objectives: Early diagnosis and treatment of inflammatory arthritis can limit 
the impact of disease outcomes. We aimed to evaluate the effectiveness of a 
referral program on the identification of patients with suspected inflammatory 
arthritis. MethOds: SIARA (Referral Strategies and Disease Education Impact 
on Diagnosis and Referral of Axial Spondyloarthritis and Rheumatoid Arthritis 
Patients) is an observational prospective, randomized (by clusters of primary care 
centers) study to analyze the impact of Referral Support Actions (RSA) consisting 
of physician educational sessions about the disease and implementation of referral 
recommendations. The participating primary care centers (n= 24) were randomly 
assigned to RSA or control group (with no intervention). Both RSA and control 
groups identified and referred patients with suspected inflammatory arthritis to 
the rheumatology unit of the reference hospital (n= 6). The main studied outcome 
is the correct diagnosis of inflammatory arthritis / rheumatoid arthritis confirmed 
by the rheumatologist of the reference hospital. Results: A total of 125 patients 
were referred to a rheumatologist (considering 4 hospitals): 61 RSA patients and 
64 control patients. Mean age was 48.9 years (range: 19-73) and 88.8% were female 
(differences not statistically significant between groups). About 14.8% (n= 9) of RSA 
patients and 4.7% (n= 3) of controls had a confirmed diagnosis of arthritis (any 
type) by the rheumatologist (OR= 3.5; 95%CI, 0.9-13.7; Chi-square p= 0.056). Rate 
of confirmed rheumatoid arthritis was 4.9% in RSA patients and 1.6% in controls 
(p= 0.287). The majority of the patients (82.0%) were referred in the 4 months after 
educational session (month 3:63.9%; month 6:96.7%). cOnclusiOns: Although the 
study results still lack statistical significance, this preliminary data already suggests 
a positive impact of a referral program on the early identification of inflammatory 
arthritis, especially after the first few months. This should be further analyzed and 
considered by healthcare deciders in order to improve health outcomes in inflam-
matory arthritis.
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Objectives: Several biosimilar products have been developed and marketed in 
Japan. However, the degree of understanding of biosimilars among healthcare pro-
fessionals is uncertain. The objective of this study was to investigate the extent 
of awareness and understanding of biosimilars among Japanese physicians and 
pharmacists. MethOds: This was a non-interventional, web-based survey con-
ducted in May 2015. Japanese physicians (rheumatologists/oncologists) and phar-
macists voluntarily participated and provided their thoughts via questionnaires. 
Rheumatologists who have seen > = 30 rheumatoid arthritis patients/month on aver-
age and have prescribed biologics (Remicade/Humira, etc.) to at least one patient, 
and oncologists who have seen > = 30 cancer patients/year with use of biologics 
(Rituxan/Avastin/Herceptin, etc.) to at least one patient were eligible. Results: Of 
screened physicians, about 35% have never heard of “biosimilar”, whereas 96% of 
pharmacists were aware of “biosimilar”. One hundred rheumatologists, 120 oncolo-
gists (30 each for Hematology/Breast/Gastroenterology/Respiratory) and 90 pharma-
cists who met the criteria and were aware of biosimilar were analyzed for a further 
questionnaire. 73% of rheumatologists and 82% of oncologists recognized that 
biosimilars “are relatively less expensive” and 62% of physicians simply answered 
“subsequent product/generic”. 58% of rheumatologists showed an intention to pre-
scribe future biosimilars, whereas 73% of oncologists showed prescription intention. 
The main reason behind this was “reduction of burden on patients”, followed by 
“confirmed similarity in efficacy/safety”. Physicians with little intention to prescribe 
biosimilars showed strong concerns for similarity to the innovator (> 70%) and insuf-
ficient clinical data in efficacy/safety perspectives. Similarities in clinical efficacy/
safety were more emphasized compared to structural and functional similarities 
in biosimilar development pathways. cOnclusiOns: Awareness of biosimilars 
amongst Japanese physicians was still low with a strong leaning toward burden on 
patients and sufficient clinical data to confirm the similarity. Providing learning 
opportunities for general tenets of biosimilarity and its development pathways are 
vital to increase public recognition of biosimilars.
